Three hospitalized non-critical COVID-19 subphenotypes and change in intubation or death over time: A latent class analysis with external and longitudinal validation
There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown. To identify and validate non-critical COVID-19 subphenotypes at hospital...
Uloženo v:
| Vydáno v: | PloS one Ročník 20; číslo 3; s. e0316434 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Public Library of Science
19.03.2025
Public Library of Science (PLoS) |
| Témata: | |
| ISSN: | 1932-6203, 1932-6203 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown.
To identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients.
We conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype.
We analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype.
We identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19. |
|---|---|
| AbstractList | BackgroundThere are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown.ObjectiveTo identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients.MethodsWe conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype.ResultsWe analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype.ConclusionWe identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19. Background There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown. Objective To identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients. Methods We conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype. Results We analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype. Conclusion We identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19. Background There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown. Objective To identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients. Methods We conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype. Results We analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype. Conclusion We identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19. There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown. To identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients. We conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype. We analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype. We identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19. There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown.BACKGROUNDThere are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown.To identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients.OBJECTIVETo identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients.We conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype.METHODSWe conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype.We analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype.RESULTSWe analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype.We identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19.CONCLUSIONWe identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19. There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes of hospitalized non-critical COVID-19 patients exist remains unknown. To identify and validate non-critical COVID-19 subphenotypes at hospital admission that may elucidate pathobiology and facilitate heterogeneity-of-treatment effect analyses of clinical trials with non-critical COVID-19 patients. We conducted a multi-center retrospective cohort study of adults hospitalized with COVID-19 who were not intubated or did not die within 24 hours of admission. We derived and externally and longitudinally validated subphenotypes during the wild-type and delta severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV2) waves via latent class analysis using clinical and laboratory data at hospital admission. We trained XGBoost machine learning models to predict subphenotype. We analyzed data for 4,827 hospitalized non-critical COVID-19 patients: 2,077 wild-type wave Columbia University Medical Center (CUMC) and affiliate hospital derivation cohort patients; 1,214 wild-type wave Cornell Medical Center and affiliate hospital external validation cohort patients; and 1,536 delta wave CUMC and affiliate hospital longitudinal validation cohort patients. A three-class latent class model best fit each cohort identifying subphenotypes that were low-inflammatory, intermediate-inflammatory, and high-inflammatory with fibrinolysis, with increasing 90-day risk of intubation or death across subphenotypes in the wild-type wave. However, in the delta wave, the intermediate-inflammatory subphenotype had the lowest 90-day risk of intubation or death. XGBoost model area under the receiver-operating-curve was 0.96 in the testing dataset, and biomarkers of inflammation and cardiorenal dysfunction were the strongest predictors of subphenotype. We identified three hospitalized non-critical COVID-19 subphenotypes that persisted through the wild-type and delta SARS-CoV2 waves. The intermediate-inflammatory subphenotype had the greatest relative improvement in intubation and survival over time with the standardized use of corticosteroids and other interventions. Our machine learning model can facilitate heterogeneity-of-treatment effect analyses of clinical trials of adults hospitalized with non-critical COVID-19. |
| Audience | Academic |
| Author | Schenck, Edward J. O’Donnell, Max R. Yang, Xuehan Geleris, Joshua D. Labar, Amy S. Berlin, David A. Cummings, Matthew J. Wei, Ying Stringer, William S. Sholle, Evan V. Yi, Haoyang McGroder, Claire M. Baldwin, Matthew R. |
| AuthorAffiliation | Stellenbosch University, SOUTH AFRICA 2 Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America 4 Department of Biostatistics, Columbia Mailman School of Public Health, New York, New York, United States of America 1 Division of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America 3 Division of Pulmonary and Critical Care Medicine, Weill Cornell University School of Medicine, New York, New York, United States of America |
| AuthorAffiliation_xml | – name: 1 Division of Pulmonary, Allergy, and Critical Care, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America – name: 4 Department of Biostatistics, Columbia Mailman School of Public Health, New York, New York, United States of America – name: 3 Division of Pulmonary and Critical Care Medicine, Weill Cornell University School of Medicine, New York, New York, United States of America – name: Stellenbosch University, SOUTH AFRICA – name: 2 Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America |
| Author_xml | – sequence: 1 givenname: William S. surname: Stringer fullname: Stringer, William S. – sequence: 2 givenname: Amy S. surname: Labar fullname: Labar, Amy S. – sequence: 3 givenname: Joshua D. surname: Geleris fullname: Geleris, Joshua D. – sequence: 4 givenname: Evan V. surname: Sholle fullname: Sholle, Evan V. – sequence: 5 givenname: David A. surname: Berlin fullname: Berlin, David A. – sequence: 6 givenname: Claire M. surname: McGroder fullname: McGroder, Claire M. – sequence: 7 givenname: Matthew J. surname: Cummings fullname: Cummings, Matthew J. – sequence: 8 givenname: Max R. surname: O’Donnell fullname: O’Donnell, Max R. – sequence: 9 givenname: Haoyang orcidid: 0009-0002-8847-8350 surname: Yi fullname: Yi, Haoyang – sequence: 10 givenname: Xuehan surname: Yang fullname: Yang, Xuehan – sequence: 11 givenname: Ying surname: Wei fullname: Wei, Ying – sequence: 12 givenname: Edward J. surname: Schenck fullname: Schenck, Edward J. – sequence: 13 givenname: Matthew R. orcidid: 0000-0003-4670-3433 surname: Baldwin fullname: Baldwin, Matthew R. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40106751$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk11v0zAUhiM0xD7gHyCwhITgosWOEyfhBlXjq9KkSjB2azn2SePJtTvbGYz_w__EWbupRbtAiRTr5Dnv8Xntc5wdWGchy54TPCW0Iu8u3eCtMNN1Ck8xJaygxaPsiDQ0n7Ac04Od9WF2HMIlxiWtGXuSHRaYYFaV5Cj7c957ANS7sNZRGP0bFEqFJtLrqKUw6HRxMf84IQ0KQ7vuwbp4s4aAhFVI9sIuAWmb3ji0ImpnkfNIgYg9ctfgUdQreI9myIgINiJpRBhzhbkJOqCfOnHwK8LYyK2kcXap46D0GLhO-1G3qk-zx50wAZ5tvyfZj8-fzk-_Ts4WX-ans7OJZEURJ3lLOsmkkh1pAHJRV1C1jWTQskp2uKGKyaLKK1GWHSUqL4E0oi4pqSiuO1nTk-zlRndtXOBbhwNPQJOYkpFEzDeEcuKSr71eCX_DndD8NuD8kgufnDPAgRGAWrJWNaLAsqgxlbQrStUSVgJlSevDttrQrkDJ5JAXZk90_4_VPV-6a05Ik-dlXiaFN1sF764GCJGvdJBgjLDghs3G8yKdepXQV_-gD7e3pZYidaBt51JhOYryWU1JjWtWjVrTB6j0KFhpme5jp1N8L-HtXkJiYjr3pRhC4PPv3_6fXVzss6932B6EiX1wZhjvTNgHX-xafe_x3SAkoNgA0rsQPHT3CMF8nLc7u_g4b3w7b_Qv3YwfDQ |
| Cites_doi | 10.1001/jamanetworkopen.2021.37257 10.1016/S2213-2600(22)00215-6 10.1016/j.chest.2016.01.003 10.1136/bmj.m3339 10.1016/S0140-6736(21)01825-0 10.1016/S2213-2600(20)30366-0 10.1016/S2213-2600(22)00298-3 10.1016/S2213-2600(14)70097-9 10.1016/S2213-2600(18)30177-2 10.1164/rccm.202105-1302OC 10.1038/s41746-021-00481-w 10.1016/S2213-2600(20)30559-2 10.1183/13993003.00780-2022 10.1016/j.chest.2021.04.062 10.1016/S0140-6736(22)01109-6 10.3348/kjr.2022.0061 10.1164/rccm.201411-2125CP 10.1080/07853890.2022.2148733 10.1016/j.chest.2021.01.057 10.1164/rccm.201603-0645OC 10.1016/S2213-2600(20)30124-7 10.1007/s00134-021-06363-9 10.1097/CCM.0000000000002514 10.1001/jama.2023.11043 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2025 Stringer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. COPYRIGHT 2025 Public Library of Science 2025 Stringer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2025 Stringer et al 2025 Stringer et al 2025 Stringer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2025 Stringer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: COPYRIGHT 2025 Public Library of Science – notice: 2025 Stringer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2025 Stringer et al 2025 Stringer et al – notice: 2025 Stringer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU COVID D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0316434 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Materials Science Collection ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agriculture Science Database ProQuest Health & Medical Collection Medical Database ProQuest Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database (ProQuest) Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database (ProQuest) Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Three hospitalized non-critical COVID-19 subphenotypes and change in intubation or death over time |
| EISSN | 1932-6203 |
| ExternalDocumentID | 3179173561 oai_doaj_org_article_e61ee8c6bd9a40c4803c3f45db165e36 PMC11922525 A831808677 40106751 10_1371_journal_pone_0316434 |
| Genre | Multicenter Study Journal Article |
| GeographicLocations | United States United Kingdom |
| GeographicLocations_xml | – name: United States – name: United Kingdom |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R21 AI171249 – fundername: NCATS NIH HHS grantid: UL1 TR001873 – fundername: NIAID NIH HHS grantid: K23 AI163364 – fundername: NHLBI NIH HHS grantid: K23 HL151876 – fundername: ; grantid: K23 AI163364 – fundername: ; grantid: R21 AI171249 – fundername: ; grantid: UL TR001873 – fundername: ; grantid: W81XWH2110217 – fundername: ; grantid: K23HL151876 – fundername: ; grantid: R01 HL16477 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACCTH ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFFHD AFKRA AFPKN AFRAH AHMBA ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAIFH BAWUL BBNVY BBTPI BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM ADRAZ ALIPV CGR CUY CVF ECM EIF IPNFZ NPM RIG BBORY 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K COVID DWQXO ESTFP FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 5PM |
| ID | FETCH-LOGICAL-c644t-2b1fc6cdcf19ee2a87e7b9c6eb67cf093d6c4727a55f31d25e19a85317308fc83 |
| IEDL.DBID | FPL |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001449697200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1932-6203 |
| IngestDate | Wed Aug 13 01:18:06 EDT 2025 Tue Oct 14 18:10:30 EDT 2025 Tue Nov 04 02:02:32 EST 2025 Sun Nov 09 12:36:11 EST 2025 Tue Oct 07 08:06:39 EDT 2025 Sat Nov 29 13:50:24 EST 2025 Sat Nov 29 10:28:20 EST 2025 Wed Nov 26 10:46:33 EST 2025 Wed Nov 26 10:47:09 EST 2025 Thu May 22 21:23:30 EDT 2025 Mon Jul 21 05:55:38 EDT 2025 Sat Nov 29 08:04:45 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright: © 2025 Stringer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c644t-2b1fc6cdcf19ee2a87e7b9c6eb67cf093d6c4727a55f31d25e19a85317308fc83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 These authors co-primary authorship on this work. Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0009-0002-8847-8350 0000-0003-4670-3433 |
| OpenAccessLink | http://dx.doi.org/10.1371/journal.pone.0316434 |
| PMID | 40106751 |
| PQID | 3179173561 |
| PQPubID | 1436336 |
| PageCount | e0316434 |
| ParticipantIDs | plos_journals_3179173561 doaj_primary_oai_doaj_org_article_e61ee8c6bd9a40c4803c3f45db165e36 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11922525 proquest_miscellaneous_3179245387 proquest_journals_3179173561 gale_infotracmisc_A831808677 gale_infotracacademiconefile_A831808677 gale_incontextgauss_ISR_A831808677 gale_incontextgauss_IOV_A831808677 gale_healthsolutions_A831808677 pubmed_primary_40106751 crossref_primary_10_1371_journal_pone_0316434 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-03-19 |
| PublicationDateYYYYMMDD | 2025-03-19 |
| PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-19 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2025 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | SR Knight (pone.0316434.ref019) 2020; 370 K Dubowski (pone.0316434.ref014) 2023; 55 SM Brown (pone.0316434.ref015) 2016; 150 ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group (pone.0316434.ref022) 2022; 10 P Sinha (pone.0316434.ref018) 2020; 8 TJ Iwashyna (pone.0316434.ref024) 2015; 192 X Wang (pone.0316434.ref010) 2021; 159 P Sinha (pone.0316434.ref004) 2021; 204 CR Vasquez (pone.0316434.ref012) 2021; 160 CS Calfee (pone.0316434.ref001) 2014; 2 RECOVERY Collaborative Group (pone.0316434.ref023) 2022; 400 C Su (pone.0316434.ref011) 2021; 4 K Han (pone.0316434.ref017) 2022; 23 JW Eikelboom (pone.0316434.ref026) 2022; 10 RK Gupta (pone.0316434.ref020) 2021; 9 RECOVERY Collaborative Group (pone.0316434.ref027) 2022; 399 JA O’Halloran (pone.0316434.ref021) 2023; 330 KR Famous (pone.0316434.ref002) 2017; 195 Q Ma (pone.0316434.ref028) 2021; 4 M Schinkel (pone.0316434.ref013) 2021; 47 K Reddy (pone.0316434.ref005) 2020; 8 SM Brown (pone.0316434.ref016) 2017; 45 pone.0316434.ref006 CS Calfee (pone.0316434.ref003) 2018; 6 pone.0316434.ref007 pone.0316434.ref029 pone.0316434.ref008 J de Brabander (pone.0316434.ref025) 2022; 60 pone.0316434.ref009 |
| References_xml | – volume: 4 start-page: e2137257 issue: 12 year: 2021 ident: pone.0316434.ref028 article-title: Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2021.37257 – volume: 10 start-page: 972 issue: 10 year: 2022 ident: pone.0316434.ref022 article-title: Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(22)00215-6 – volume: 150 start-page: 307 issue: 2 year: 2016 ident: pone.0316434.ref015 article-title: Nonlinear imputation of Pao2/Fio2 from Spo2/Fio2 among patients with acute respiratory distress syndrome publication-title: Chest doi: 10.1016/j.chest.2016.01.003 – volume: 370 start-page: m3339 year: 2020 ident: pone.0316434.ref019 article-title: Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score publication-title: BMJ doi: 10.1136/bmj.m3339 – volume: 399 start-page: 143 issue: 10320 year: 2022 ident: pone.0316434.ref027 article-title: Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial publication-title: Lancet doi: 10.1016/S0140-6736(21)01825-0 – volume: 8 start-page: 1209 issue: 12 year: 2020 ident: pone.0316434.ref018 article-title: Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30366-0 – volume: 10 start-page: 1169 issue: 12 year: 2022 ident: pone.0316434.ref026 article-title: Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(22)00298-3 – ident: pone.0316434.ref007 – volume: 2 start-page: 611 issue: 8 year: 2014 ident: pone.0316434.ref001 article-title: Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(14)70097-9 – volume: 6 start-page: 691 issue: 9 year: 2018 ident: pone.0316434.ref003 article-title: Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(18)30177-2 – volume: 204 start-page: 1274 issue: 11 year: 2021 ident: pone.0316434.ref004 article-title: Latent class analysis reveals COVID-19-related acute respiratory distress syndrome subgroups with differential responses to corticosteroids publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.202105-1302OC – ident: pone.0316434.ref009 – volume: 4 start-page: 110 issue: 1 year: 2021 ident: pone.0316434.ref011 article-title: Clinical subphenotypes in COVID-19: derivation, validation, prediction, temporal patterns, and interaction with social determinants of health publication-title: NPJ Digit Med doi: 10.1038/s41746-021-00481-w – volume: 9 start-page: 349 issue: 4 year: 2021 ident: pone.0316434.ref020 article-title: Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30559-2 – volume: 60 start-page: 2200780 issue: 6 year: 2022 ident: pone.0316434.ref025 article-title: Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients publication-title: Eur Respir J doi: 10.1183/13993003.00780-2022 – volume: 160 start-page: 929 issue: 3 year: 2021 ident: pone.0316434.ref012 article-title: Identification of distinct clinical subphenotypes in critically ill patients with COVID-19 publication-title: Chest doi: 10.1016/j.chest.2021.04.062 – volume: 400 start-page: 359 issue: 10349 year: 2022 ident: pone.0316434.ref023 article-title: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(22)01109-6 – volume: 23 start-page: 495 issue: 5 year: 2022 ident: pone.0316434.ref017 article-title: Restricted mean survival time for survival analysis: a quick guide for clinical researchers publication-title: Korean J Radiol doi: 10.3348/kjr.2022.0061 – volume: 192 start-page: 1045 issue: 9 year: 2015 ident: pone.0316434.ref024 article-title: Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201411-2125CP – volume: 55 start-page: 12 issue: 1 year: 2023 ident: pone.0316434.ref014 article-title: COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study publication-title: Ann Med doi: 10.1080/07853890.2022.2148733 – ident: pone.0316434.ref006 – volume: 159 start-page: 2191 issue: 6 year: 2021 ident: pone.0316434.ref010 article-title: Phenotypes and subphenotypes of patients with COVID-19: a latent class modeling analysis publication-title: Chest doi: 10.1016/j.chest.2021.01.057 – volume: 195 start-page: 331 issue: 3 year: 2017 ident: pone.0316434.ref002 article-title: Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy publication-title: Am J Respir Crit Care Med doi: 10.1164/rccm.201603-0645OC – volume: 8 start-page: 631 issue: 6 year: 2020 ident: pone.0316434.ref005 article-title: Subphenotypes in critical care: translation into clinical practice publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30124-7 – volume: 47 start-page: 482 issue: 4 year: 2021 ident: pone.0316434.ref013 article-title: Association of clinical sub-phenotypes and clinical deterioration in COVID-19: further cluster analyses publication-title: Intensive Care Med doi: 10.1007/s00134-021-06363-9 – volume: 45 start-page: 1317 issue: 8 year: 2017 ident: pone.0316434.ref016 article-title: Nonlinear imputation of PaO2/FIO2 from SpO2/FIO2 among mechanically ventilated patients in the ICU: a prospective, observational study publication-title: Crit Care Med doi: 10.1097/CCM.0000000000002514 – ident: pone.0316434.ref008 – ident: pone.0316434.ref029 – volume: 330 start-page: 328 issue: 4 year: 2023 ident: pone.0316434.ref021 article-title: Abatacept, cenicriviroc, or infliximab for treatment of adults hospitalized with COVID-19 pneumonia: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2023.11043 |
| SSID | ssj0053866 |
| Score | 2.4736722 |
| Snippet | There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar subphenotypes... Background There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar... BackgroundThere are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar... Background There are two subphenotypes of COVID-19 acute respiratory distress syndrome with differential responses to corticosteroids, but whether similar... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0316434 |
| SubjectTerms | Acute respiratory distress syndrome Adult Adults Aged Analysis Biology and Life Sciences Biomarkers C-reactive protein Care and treatment Clinical trials Coronaviruses Corticoids Corticosteroids COVID-19 COVID-19 - mortality COVID-19 - pathology COVID-19 - therapy COVID-19 - virology Death Emergency medical care Entropy Female Fibrinolysis Forecasts and trends Health aspects Health care facilities Health services Heterogeneity Hospitalization Hospitals Humans Inflammation Intubation Latent Class Analysis Learning algorithms Longitudinal Studies Machine Learning Male Medical research Medicine and Health Sciences Medicine, Experimental Middle Aged Mortality Patients Phenotype Physical Sciences Probability Research and Analysis Methods Respiratory distress syndrome Retrospective Studies Risk factors Rivaroxaban SARS-CoV-2 - isolation & purification Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 United States Variables Vital signs |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxMxELZQxIELorwaKGAQEnDYdh9-cguFikqoRVCq3lZe20sjRbtRNsuB_8P_ZGbtRF1UCQ5IOcVjKzvzeTyzGX9DyEutnVHWuET52ieMVXmirWWJYxXzrFC8CpT5n-TJibq40J-vtPrCmrBADxwUd-BF5r2yonLasNQylRa2qBl3VSa4Lway7VTqTTIVfDDsYiHiRblCZgfRLvvLtvH7AGM4htnoIBr4-rdeebJctN11IeeflZNXjqKjO-R2jCHpLPz2HXLDN3fJTtylHX0dqaTf3CO_zsBUnl7G5iDzn95RyPcTGxsc0MPT8-P3SaZp11dY7dXiK9mOmsbRcCWYzhv4rPtqsCBtV9Rh0Eix8pNiY_q3dEYXELA2a2oxEoe5geaE4iteumGZHpZctNgdqXfYiYsCxOehodN98u3ow9nhxyQ2ZkgshE_rJK-y2grrbJ1p73OjpJeVtsJXQto61YUTlkFgZDivi8zl3GfaQFyQgTtRtVXFAzKBh_W7hDqIAKUwzkghmJMWcnWeO2EEqyTn0k5JsrFSuQz8G-XwJ5yEvCWou0SrltGqU_IOTbmVRfbs4QvAVBkxVf4NU1PyDIFQhquoWx9QzhR4wBQZAKfkxSCBDBoNluh8N33Xlcen5_8g9PXLSOhVFKpbgJQ18VoEPBMyc40k90aS4AfsaHgXYbvRSlcWyDwrCwiQYeYGytcPP98O46JYdtf4tg8yOYPdBKs_DMjfapYN7IMcZqvRnhipfjzSzC8HAvMM0oqc5_zR_zDWY3Irx57MWGOp98hkver9E3LT_ljPu9XTwS38Blr_a5A priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. dbid: 7RV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZg4cAFKI92oYBBSMDB7SbxK1zQUqiohFpUStVb5NhOu9IqWTYbDvwf_iczibMQVCEkpJzisRXb34zHzvgbQp6nqTPaGse0LzzjPI9Zai1njufc80SLvKPM_6gOD_XZWfopHLjVIayyt4mtoXaVxTPy3QR5NFUCy_2bxVeGWaPw72pIoXGVXIvQNwY8q-PT3hKDLksZrsslKtoNs7OzqEq_A2CGxZgPlqOWtX9tm0eLeVVf5nj-GT_524K0f-t_u3Kb3AyuKJ122NkgV3x5h2wEZa_py8BI_eou-XECM-7pRcgxMvvuHS2rktmQJ4HuHZ0evGNRSusmx6CxCk92a2pKR7ubxXRWwrNq8hYItFpSh74nxQBSivntX9MpnYPfW66oRYce6nZsKRRPimlPVt02Oa8wyVLjMKEXBU2ZdXmh7pEv--9P9j6wkN-BWfDCVizOo8JK62wRpd7HRiuv8tRKn0tli0maOGk5-FdGiCKJXCx8lBpwL2DsJrqwOrlPRtBZv0WoA0dSSeOMkpI7ZWHLL2InjeS5EkLZMWH9NGeLjsYja__lKdj-dMOdISyyAIsxeYtYWMsiCXf7olqeZ0GnMy8j77WVuUsNn1iuJ4lNCi5cHknhEzkmTxBJWXejdW1KsqkGQzpBIsExedZKIBFHiZE-56ap6-zg6PQfhD4fD4ReBKGiAkxaE25XQJ-Q4GsguT2QBHNiB8VbiPt-VOrsF1qhZo_ny4ufrouxUYzeK33VdDIxB3WE1jc71VmPLG9JDAXU1gOlGgz9sKScXbQ86BHsTmIRiwd__66H5EaMSZsxCDPdJqPVsvGPyHX7bTWrl49bi_ETWTF5TA priority: 102 providerName: ProQuest |
| Title | Three hospitalized non-critical COVID-19 subphenotypes and change in intubation or death over time: A latent class analysis with external and longitudinal validation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40106751 https://www.proquest.com/docview/3179173561 https://www.proquest.com/docview/3179245387 https://pubmed.ncbi.nlm.nih.gov/PMC11922525 https://doaj.org/article/e61ee8c6bd9a40c4803c3f45db165e36 http://dx.doi.org/10.1371/journal.pone.0316434 |
| Volume | 20 |
| WOSCitedRecordID | wos001449697200015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Advanced Technologies & Aerospace Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: P5Z dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: Agriculture Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M0K dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/agriculturejournals providerName: ProQuest – providerCode: PRVPQU databaseName: Biological Science Database (ProQuest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7P dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: M7S dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Environmental Science Database (ProQuest) customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PATMY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/environmentalscience providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7X7 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Materials Science Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: KB. dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/materialsscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 7RV dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: BENPR dateStart: 20061201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: 8C1 dateStart: 20061201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: PIMPY dateStart: 20061201 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVATS databaseName: Public Library of Science (PLoS) Journals Open Access customDbUrl: eissn: 1932-6203 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0053866 issn: 1932-6203 databaseCode: FPL dateStart: 20060101 isFulltext: true titleUrlDefault: http://www.plos.org/publications/ providerName: Public Library of Science |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELfYxgMvwPhaYRSDkICHjCbxV3jbxiambV3UjWrjJUpsh1WakqppeOD_4f_kzkkLmTYJpOoe6rOV-D58ds6_I-RtFJlU6dR4yubWYywLvEhr5hmWMctCxbMGMv9IDofq_DyK_2wUr33BD6X_sZ3TrWlZ2C1QQVhC2QpZC0IhcLO1Hx8tPC_YrhDt9bjbenaWH4fSv_TFq9Orsrop0LyeL_nXArT_4H8f_SG534aadLvRjXVyxxaPyHprzBV93yJOf3hMfp2BRC29bGuITH5aQ4uy8HRbB4HunowPPnt-RKs6w6SwEk9uK5oWhjY3h-mkgN-8zpygaTmjBmNLigmiFOvXf6Lb9Ari2mJONQbs0LdBQ6F4EkwXYNRuyKsSiyjVBgt2UbCESVP36Qn5ur93tvvFa-s3eBqirLkXZH6uhTY69yNrg1RJK7NIC5sJqfNBFBqhGcRPKed56JuAWz9KIXzwweuoXKvwKVmFl7UbhBoIFKVITSqFYEZq2NLzwIhUsExyLnWPeAuxJtMGpiNx3-okbG-a6U5QCkkrhR7ZQdkveRFk2_0B4ktam02s8K1VWmQmStlAMzUIdZgzbjJfcBuKHnmFmpM0N1aXriLZVuAoBwgU2CNvHAcCbRSYyfM9rasqOTgZ_wPT6ajD9K5lykvQQZ22tyfgnRDAq8O52eEEd6E7zRuo54tZqZIQAWplCHE09Fzo_s3Nr5fNOChm5xW2rBuegIH5wejPGlNZzixzIIUcequOEXWmvttSTC4dzrkPu4-AB_z57Y_8gtwLsCAzJlhGm2R1PqvtS3JX_5hPqlmfrMjRGOm5dFQBVbt-n6zt7A3jUd8dwPSdDwF6uLMF9HhwiFTGjp4Cjfk36BEfHMcXvwGbcnQC |
| linkProvider | Public Library of Science |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELdGQYIXYHytMJhBIOAhW5M4doKEUNmYVq1sE5Rp4iU4trNFKklpEhD8P7zyN3KXj0LQhHjZA1Kf6oubXO93d3bOvyPkYRBo6SupLd_ExmIscqxAKWZpFjHDXN-Lasr8sdjb84-OgoMl8qM9C4Nlla1PrBy1zhTukW-4yKMpXAj3L2afLOwahW9X2xYatVnsmq9fYMmWPx9twf_7yHG2X002d6ymq4ClIPYXlhPZseJKq9gOjHGkL4yIAsVNxIWKYYGvuWIQ1aXnxa6tHc_YgYSgBj8-8GPluzDvOXKeMWeAKDrw3reeH3wH583xPFfYG401rM-y1KwDeCD4s074q7oELGJBbzbN8tMS3T_rNX8LgNtX_jfVXSWXm1SbDmtsLJMlk14jy40zy-mThnH76XXyfQIWbehJ00Ml-WY0TbPUUk0fCLq5fzjasuyA5mWERXEZ7lznVKaa1ienaZLCpyijytBpNqcac2uKBbK0SD6aZ3RIp5DXpwVVuGCBa2s2GIo74bQl466mnGbYRKrU2LCMgidI6r5XN8i7M1HXTdKDhzUrhGpIlAWXWgrOmRYqgEzP0VxyFgnPE6pPrNaswllNUxJW7yoFLO9qdYdohmFjhn3yEm1vIYsk49UX2fw4bHxWaLhtjK94pAPJBor5A1e5MfN0ZHPPuLxP1tByw_rE7sJVhkMfAsUAiRL75EElgUQjKVYyHcsyz8PR_uE_CL190xF63AjFGWBAyeb0CDwTEph1JFc7kuAuVWd4BXHWaiUPf6EDrmzxc_rw_cUwTorVianJylrGYQB_mP1WDdWFZllF0ujB1X4HxB3Vd0fS5KTiebdh9eV4jnf77_e1Ri7uTF6Pw_Fob_cOueRgg2osOA1WSa-Yl-YuuaA-F0k-v1d5K0o-nDXGfwKrfddB |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1fb9MwELdGQYgXYPxbYTCDQMBD1iZx7AQJobJSUW3qKhjTxEtIbGerVJLSJCD4PnwJPh13iVMImhAve0DKU3y2ksv9dc6_I-RhEKjIl5GyfJ1oi7HYsQIpmaVYzDRzfS-uIfP3xGTiHx0F0zXyozkLg2WVjU2sDLXKJO6R91zE0RQuuPteYsoipsPRi8UnCztI4Z_Wpp1GLSK7-usXSN_y5-MhfOtHjjN6dbDz2jIdBiwJcUBhObGdSC6VTOxAayfyhRZxILmOuZAJJPuKSwYePvK8xLWV42k7iMDBwYP0_UT6Lqx7jpwXkGNiOeHUe994AbAjnJujeq6we0YythdZqrdBkSAQYC1XWHUMWPmFzmKe5acFvX_Wbv7mDEdX_mc2XiWXTQhOB7XOrJM1nV4j68bI5fSJQeJ-ep18PwBJ1_TE9FaZfdOKpllqSdMfgu7sH46Hlh3QvIyxWC7DHe2cRqmi9YlqOkvhKsq4UgCaLanCmJti4SwtZh_1Mzqgc4j304JKTGRgbo0SQ3GHnDYg3dWS8wybS5UKG5lRsBCzuh_WDfLuTNh1k3TgZfUGoQoCaMEjFQnOmRIygAjQUTziLBaeJ2SXWI2IhYsaviSs_mEKSPtqdocokqERyS55iXK4okXw8epGtjwOjS0LNbe19iWPVRCxvmR-35VuwjwV29zTLu-SLZTisD7JuzKh4cAHB9JHAMUueVBRIABJijJ4HJV5Ho73D_-B6O2bFtFjQ5RkoA8yMqdK4J0Q2KxFudmiBDMqW8MbqHMNV_Lwl6bAzEaXTh--vxrGRbFqMdVZWdM4DEwBrH6rVtsVZ1kF3ujBbL-l0C3Wt0fS2UmF_25DVuZ4jnf778-1RS6Caod748nuHXLJwb7VWIcabJJOsSz1XXJBfi5m-fJeZbgo-XDWKv4T9gngCw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Three+hospitalized+non-critical+COVID-19+subphenotypes+and+change+in+intubation+or+death+over+time%3A+A+latent+class+analysis+with+external+and+longitudinal+validation&rft.jtitle=PloS+one&rft.au=Stringer%2C+William+S&rft.au=Labar%2C+Amy+S&rft.au=Geleris%2C+Joshua+D&rft.au=Sholle%2C+Evan+V&rft.date=2025-03-19&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=20&rft.issue=3&rft.spage=e0316434&rft_id=info:doi/10.1371%2Fjournal.pone.0316434&rft.externalDocID=A831808677 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |